Viyash Scientific FY26: Revenue ₹13,820.6 Crore, Net Profit ₹758.7 Crore; ESOP 1.3 Crore Shares Granted
Viyash Scientific Limited's board approved audited financial results for the year ended March 31, 2026, with revenue from operations at ₹13,820.6 crore (₹138,206 million) and a profit after tax of ₹758.7 crore (₹7,587 million). The board also approved granting 1.3 Crore (13,098,000) stock options to eligible employees under the 'Viyash Scientific Limited Employee Stock Option Scheme 2026'. No dividend was recommended for FY 2025-26.
The financial results and ESOP grant are significant but not transformative. The lack of dividend may be a minor negative for some investors.
The announcement includes positive financial results, such as increased revenue and profit, and the approval of employee stock options, which generally boosts employee morale and investor confidence.
Viyash Scientific Limited (formerly known as Sequent Scientific Limited) announced the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the adoption of new Articles of Association, subject to shareholder approval. Additionally, the board approved the grant of 1,30,98,000 (One Crore Thirty Lakhs Ninety-Eight Thousand) stock options to eligible employees under the “Viyash Scientific Limited Employee Stock Option Scheme 2026”.
The company has not recommended any dividend for FY 2025-26 to conserve resources. The Board Meeting, held on May 19, 2026, commenced at 3:00 p.m. and concluded at 4:56 p.m.
The standalone financial results show revenue from operations of ₹13,820.6 crore (₹138,206 million) and a profit after tax of ₹758.7 crore (₹7,587 million) for the year ended March 31, 2026. The company is not a Large Corporate for FY 2025-26.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.